AlpInvest Partners’s Aimmune Therapeutics AIMT Stock Holding History

AlpInvest Partners’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-38,943	Closed	-$1.06M	–	28
2018 Q3	$1.06M	Hold	38,943	–	–	2.27%	11
2018 Q2	$1.05M	Hold	38,943	–	–	4.37%	7
2018 Q1	$1.24M	Sell	38,943 -12,555	-24%	-$442K	11.17%	3
2017 Q4	$1.95M	Buy	+51,498	New	+$1.66M	6.95%	5

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AlpInvest Partners's AIMT Position: Q4 2018 in Review

AlpInvest Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 38,943 shares — an estimated $1.06M sold.

AlpInvest Partners first reported a position in AIMT in Q4 2017 and held it in 4 quarters. The position peaked at $1.95M in Q4 2017. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

AlpInvest Partners reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
AlpInvest Partners sold 38,943 Aimmune Therapeutics shares in Q4 2018, an estimated $1.06M.
AlpInvest Partners first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 4 quarters.
AlpInvest Partners's Aimmune Therapeutics position peaked at $1.95M in Q4 2017.
132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on AlpInvest Partners's 13F filing for Q4 2018, filed 14 Feb 2019.